Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How does nintedanib overcome cancer drug-resistant mutation of RET protein-tyrosine kinase: insights from molecular dynamics simulations.

Journal of molecular modeling - 2 Nov 2021

Cao Shu, Jiang Xu, Tan Changbin, Fu Ming, Xiong Wenqing, Ji Dong, Lv Jun

Abstract excerpt

Targeted drug therapies represent a therapeutic breakthrough in the treatment of human cancer. However, the emergence of acquired resistance inevitably compromises therapeutic drugs. Rearranged during transfection (RET) proto-oncogene, which encodes a receptor tyrosine kinase, is a target for several kinds of human cancer such as thyroid, breast, and colorectal carcinoma. A single mutation L881V at the RET kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Medullary
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Molecular Dynamics Simulation

Share to Multiple Endocrine Neoplasia Type 2a

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins c-ret

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 34725737
DOI: 10.1007/s00894-021-04964-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How does nintedanib overcome cancer drug-resistant mutation of RET protein-tyrosine kinase: insights from molecular dynamics simulations.PMID 34725737Read ↗

Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations.Semantic proximity Read ↗

In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach.Semantic proximity Read ↗

Characterization of wild-type and mutated RET proto- oncogene associated with familial medullary thyroid cancer.Semantic proximity Read ↗

Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.Semantic proximity Read ↗

Molecular Dynamic Simulations and Binding Free Energy Evaluations of Thiazolo-[2,3-b] Quinazolinone Derivatives With wtEGFR-TKD and "TMLR" Mutant EGFR-TKDSemantic proximity Read ↗

Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches.Semantic proximity Read ↗

Molecular dynamic simulations based discovery and development of thiazolidin-4-one derivatives as EGFR inhibitors targeting resistance in non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Molecular dynamics study of enhanced autophosphorylation by S904F mutation of the RET kinase domain.Semantic proximity Read ↗

Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors.Semantic proximity Read ↗

Drug resistance profiles of mutations in the RET kinase domain.Semantic proximity Read ↗

Exploring binding stability of hydroxy-3-(4-hydroxyphenyl)-5-(4-nitrophenyl)-5,5a,7,8,9,9a-hexahydrothiazolo[2,3-b] quinazolin-6-one with T790M/L858R EGFR-TKD.Semantic proximity Read ↗

Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.